Literature DB >> 19029822

TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.

Andrew D Darnel1, Christopher J Lafargue, Robin T Vollmer, Jacques Corcos, Tarek A Bismar.   

Abstract

PURPOSE: TMPRSS2-ERG gene fusion was recently reported as the most common gene rearrangement in prostate cancer (PCA).
RESULTS: In this cohort 41% of the patients showed positive gene fusion status in their PCA. The TMPRSS2-ERG gene fusion status was homogenous within the same cancer focus and 82% of fusion positive PCA were present in GS 6 or 7 vs. 14% in GS 8 (p = 0.004). Moreover, TMPRSS2-ERG fusion was present in 42% of Gleason pattern 3 vs. 27% of Gleason pattern 4 (p = 0.014). However, in this study, no significant association was noticed between TMPRSS2-ERG fusion status in relation to pathological stage, surgical margin or biochemical failure. EXPERIMENTAL
DESIGN: Using break-apart FISH assay to indirectly assess the fusion of TMPRSS2-ERG. We sought to characterize the incidence, pathological features and clinical parameters of TMPRSS2-ERG gene fusion in a cohort of 196 Canadian men treated by radical prostatectomy for localized PCA, and to investigate its potential as a biomarker in PCA.
CONCLUSION: The higher association of TMPRSS2-ERG with Gleason score 6 and 7 should be further investigated. If confirmed, this could have significant clinical impact in further stratifying patients with PCA should the TMPRSS2-ERG be confirmed as a prognostic biomarker.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19029822     DOI: 10.4161/cbt.8.2.7134

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  28 in total

1.  ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.

Authors:  Raymond B Nagle; Amit M Algotar; Connie C Cortez; Katherine Smith; Carol Jones; Ubaradka G Sathyanarayana; Steven Yun; Janice Riley; Dea Nagy; Ryan Dittamore; Bruce Dalkin; Laura Brosh; Gary Pestano
Journal:  Prostate       Date:  2013-05-07       Impact factor: 4.104

2.  TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens.

Authors:  Ömer Yılmaz; Ufuk Berber; Sezgin Okçelik; Hasan Soydan; Ferhat Ateş; Kenan Karademir
Journal:  Turk J Urol       Date:  2016-06

3.  High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.

Authors:  Adrian Box; Mohammed Alshalalfa; Samar A Hegazy; Bryan Donnelly; Tarek A Bismar
Journal:  Tumour Biol       Date:  2016-06-07

4.  The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Authors:  Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

Review 5.  ERG expression in prostate cancer: biological relevance and clinical implication.

Authors:  Hatem Abou-Ouf; Liena Zhao; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-28       Impact factor: 4.553

6.  ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.

Authors:  K-C Huang; M Dolph; B Donnelly; T A Bismar
Journal:  Clin Transl Oncol       Date:  2014-05-06       Impact factor: 3.405

7.  TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.

Authors:  Samson W Fine; Anuradha Gopalan; Margaret A Leversha; Hikmat A Al-Ahmadie; Satish K Tickoo; Qin Zhou; Jaya M Satagopan; Peter T Scardino; William L Gerald; Victor E Reuter
Journal:  Mod Pathol       Date:  2010-06-18       Impact factor: 7.842

8.  ETS gene fusions and prostate cancer.

Authors:  Wei Huang; Michelle Waknitz
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

9.  TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Authors:  Anuradha Gopalan; Margaret A Leversha; Maria E Dudas; Alexandra C Maschino; Jeremy Chang; Hikmat A Al-Ahmadie; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; Samson W Fine
Journal:  Histopathology       Date:  2013-05-23       Impact factor: 5.087

10.  Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Authors:  Martine P Roudier; Brian R Winters; Ilsa Coleman; Hung-Ming Lam; Xiaotun Zhang; Roger Coleman; Lisly Chéry; Lawrence D True; Celestia S Higano; Bruce Montgomery; Paul H Lange; Linda A Snyder; Shiv Srivastava; Eva Corey; Robert L Vessella; Peter S Nelson; Aykut Üren; Colm Morrissey
Journal:  Prostate       Date:  2016-03-16       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.